Search Results
Your search for The A,The A matches 32354 pages
Showing 25501 - 25550Living and Working with Cancer
The most recent figures from the National Cancer Institute put the number of cancer survivors in the United States at nearly 14 million—by 2022, that number is expected to top 18 million. And for the vast majority of those survivors—more than 80%—returning to work after treatment is a top priority...
Western Science Catching Up with Traditional Chinese Medicine
Since the National Institutes of Health Consensus Statement in 1997 concluded that the evidence to date suggests acupuncture is effective in the treatment of chemotherapy-induced nausea and vomiting,1 numerous additional indications for its use in relieving symptoms related to cancer or its...
Acupuncture May Reduce Arm Lymphedema in Patients with Breast Cancer
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance S. Rockefeller Chair in Integrative Medicine at Memorial Sloan-Kettering Cancer Center, New York. The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center...
David Penson, MD, MPH, Receives $2 Million Research Award to Study Prostate Cancer
David Penson, MD, MPH, Professor of Urologic Surgery, Vanderbilt University Medical Center, Nashville, has received a $2 million research award from the Patient-Centered Outcomes Research Institute to study localized prostate cancer. Dr. Penson is also Director of the Vanderbilt Center for Surgical ...
SIDEBAR: Key Issues in Joint Commission Statement by American Psychosocial Oncology Society, Association of Oncology Social Work, and Oncology Nursing Society
It is imperative that [Commission on Cancer]-accredited programs adopt a universal definition of distress. We concur with the National Comprehensive Cancer Network definition of distress as an “unpleasant emotional experience of a psychological (cognitive, behavioral, emotional), social, and/or...
Professional Societies Endorse 2015 Standard for Cancer Center Accreditation by Commission on Cancer
In 2015, the American College of Surgeons (ACoS) Commission on Cancer (CoC) will require cancer centers to implement screening programs for psychosocial distress as a new criterion for accreditation. The American Psychosocial Oncology Society (APOS) recently announced recommendations to support a...
Adolescents, Young Adults with Cancer Often Challenged By Unmet Needs Following Treatment
About 70,000 adolescents and young adults (AYAs) between the ages of 15 and 39 are diagnosed with cancer each year, and in the past 30 years, there has been little or no improvement in survival in this population. In addition to the disease itself, they face many other challenges: reentry into...
SIDEBAR: Required Reporting
Applicable manufacturers are required to report to the Centers for Medicare & Medicaid Services the following types of payment: Consulting fees Compensation for services other than consulting, including serving as faculty or as a speaker at an event other than a continuing education program ...
SIDEBAR: 'Covered Recipients'
The Sunshine Act calls for disclosure by manufacturers of payments to “covered recipients.” A covered recipient is a teaching hospital or any physician who is currently licensed and legally authorized to practice, except for a physician who is an employee of the applicable manufacturer that is...
SIDEBAR: Key Dates
Applicable manufacturers and group purchasing organizations must begin data collection in connection with the requirements of the Sunshine Act on August 1, 2013. The first reports must be filed with the Centers for Medicare & Medicaid Services (CMS) by March 31, 2014. CMS will release the...
The Sunshine Act Calls for Greater Transparency in Industry-Doctor Relationships
Signed into law on March 23, 2010, the Patient Protection and Affordable Care Act represents the most significant overhaul of the U.S. health-care system since the passage of Medicare and Medicaid in 1965. Because of the law’s sheer scope, parts of it still remain obfuscated by its 2,400 or so...
Focus on the West Virginia Oncology Society
Now in its fifth year, the West Virginia Oncology Society (WVOS) is already having a major impact on cancer care in the state. In 2010, a joint initiative to develop a statewide cancer clinical trials network was launched by WVOS and the West Virginia University Cancer Center. With funding support...
Significant Improvement in Overall Survival Seen with Pemetrexed Maintenance after Pemetrexed/Cisplatin Induction in Patients with Advanced NSCLC
In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final overall...
Intercalated Chemotherapy/Erlotinib Improves Progression-free Survival in Advanced NSCLC
EGFR mutation status may not be known at the time treatment is started in patients with advanced non–small cell lung cancer (NSCLC). Further, some data suggest that the efficacy of concurrent treatment with an EGFR tyrosine kinase inhibitor and chemotherapy is reduced because the G1 cell-cycle...
Link between Red Meat Consumption and Mortality Clarified in Patients with Nonmetastatic Colorectal Cancer
Evidence shows that diets high in red and processed meat are associated with an increased risk of colorectal cancer. In a study reported in the Journal of Clinical Oncology, Marjorie L. McCullough, ScD, Strategic Director of Nutritional Epidemiology, and colleagues from the Epidemiology Research...
Docetaxel Superior to Erlotinib in Second-line Treatment of Advanced Non–Small Cell Lung Cancer with Wild-type EGFR
There is ongoing debate about the efficacy of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC) whose tumors have wild-type EGFR. In the TAILOR trial, reported in Lancet Oncology by Garassino and colleagues,1 erlotinib was compared with standard docetaxel as...
First-line Carboplatin/Pemetrexed Improves Survival vs Pemetrexed Alone in Advanced Lung Cancer
A significant proportion of patients with advanced non–small cell lung cancer (NSCLC) have poor performance status, and optimal clinical management of these patients has not been established. In an attempt to help define optimal chemotherapy in such patients, Mauro Zukin, MD, of Instituto Nacional...
30 Years of Identifying High-Quality Research with Breakthrough Potential
Today, cancer research happens on many compelling fronts. At the Conquer Cancer Foundation, our focus is on clinical and translational research—that is, prudently and swiftly translating research findings to enhance the care of patients with cancer in hospitals, clinics, physicians’ offices, and...
Policy Update Aims to Advance Tobacco Cessation and Control Worldwide
In response to scientific advances and the evolving regulatory and policy environment, ASCO recently released an update to its 2003 policy statement on tobacco cessation and control. The statement reviews advancements that have been made since 2003 and outlines a refined set of recommendations...
ASCO's Guideline on Drugs to Lower Breast Cancer Risk
Direct your patients to www.cancer.net/whattoknow so they can learn about ASCO’s recent guideline on drugs to risk of breast cancer for women who have a high risk of developing the disease, including what the recommendations mean for patients and a list of questions to ask the doctor. In addition,...
Conquer Cancer Foundation Grant Recipient 'Pays It Forward' Through Philanthropic Support, Volunteer Service
Dr. Dawn Hershman, Associate Professor of Medicine and Epidemiology at Columbia University Medical Center and leader of the Breast Cancer Program at Herbert Irving Comprehensive Cancer Center, is committed to doing what she can to develop, encourage, and support the next generation of oncology...
Study Evaluates Post-Traumatic Stress Symptoms in Young Adults with Cancer
Researchers at the University of Michigan recently reported that young adults with cancer should try to stay occupied with school, work, and other usual activities during the year after their cancer diagnosis to become less vulnerable to post-traumatic stress symptoms. The study was recently...
A Look Ahead: The Next Decade in Pediatric Oncology
The past 10 years have seen dramatic advances in cancer care, especially in better screening methods and earlier detection, genomic sequencing, and more effective therapies, which have led to increased survival rates in both childhood and adult cancers. According to the National Cancer Institute...
TV Celebrity Valerie Harper Joins Lung Cancer Foundation in Raising Awareness
Actress and lung cancer advocate Valerie Harper and her husband Tony Cacciotti joined other lung cancer advocates and supporters recently at the Lung Cancer Foundation of America’s “Day at the Races” at the Del Mar Race Track in Del Mar, California. Ms. Harper is currently fighting lung cancer that ...
Infertility in Men Raises Their Risk for Cancer
A cohort study of 2,238 men who were evaluated for infertility at a clinic in Texas from 1989 to 2009 found that those men who had azoospermia, a condition in which no measurable sperm is present, had a 2.2-fold higher cancer risk compared with those who were nonazoospermic. The study was published ...
Michael J. Stamos, MD, Elected ASCRS President, Terry C. Hicks, MD, Chosen President-Elect
Michael J. Stamos, MD, Orange, California, was elected President of the American Society of Colon and Rectal Surgeons (ASCRS) at the Society’s Annual Meeting in Phoenix, succeeding Alan G. Thorson, MD, Omaha. Dr. Stamos is the John E. Connolly Professor and Chair of the Department of Surgery at the ...
American Association for Cancer Research Foundation Appoints New Executive Director
The American Association for Cancer Research (AACR) recently announced the appointment of Mitchell R. Stoller as Executive Director of the AACR Foundation for the Prevention and Cure of Cancer. In his role, Mr. Stoller will lead strategy and work closely with the AACR Foundation Board of Trustees...
SIDEBAR: Program Background
Partners for Cancer Care and Prevention holds that early detection and high-quality treatment of breast and cervical cancer save lives. The organization exists to build community capacity for the creation of high-quality, holistic breast and cervical health programs managed by the local health...
Program Aims to Overcome Barriers to Early Cancer Care in Colombia
According to a report from the International Agency for Research on Cancer’s GLOBOCAN project, one woman dies every minute from breast cancer and one woman dies every 2 minutes from cervical cancer.1 The majority of these deaths occur in developing countries, where access to health care is limited ...
Whole-exome Sequencing of NCI-60 Cell Line Panel Provides Genomic Resource for Cancer Biology and Pharmacology
The NCI-60 cell lines, which represent cancers of the lung, colon, brain, ovary, breast, prostate, and kidney, as well as leukemia and melanoma, are the most frequently studied human tumor cell lines in cancer research and have generated the most extensive cancer pharmacology database worldwide. As ...
AACR Cautions Diminished NIH Funding Jeopardizes Ability to Eradicate Cancer Health Disparities
Recently the American Association for Cancer Research (AACR) hosted a congressional briefing to highlight the significance of federally funded biomedical research in improving our understanding of cancer health disparities and developing targeted interventions to eliminate them. Disproportionate...
Is Age Truly Relative in HER2-Positive Breast Cancer?
Breast cancer arising in younger women has increasingly become the subject of intense study, and often debate, over the past decade. Retrospective studies have illustrated that breast cancer in young women is more commonly an aggressive subtype (ie, triple-negative/basal-like, HER2-enriched),...
Age Not Linked to Recurrence in Observation or Trastuzumab Groups with HER2-positive Breast Cancer
Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...
Further Support for Front-line Targeted EGFR Therapy
LUX-Lung 3 is the sixth, and largest, prospective, randomized trial to evaluate targeted EGFR inhibition vs front-line platinum doublet chemotherapy for patients with EGFR mutations. LUX-Lung 3 distinguishes itself from the previous trials (see Table 1) by using afatinib (Gilotrif), a...
LUX-Lung 3: Afatinib Prolongs Progression-free Survival vs Cisplatin/Pemetrexed in Advanced Lung Adenocarcinoma
Afatinib (Gilotrif) is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has exhibited broad-spectrum activity against EGFR mutations in preclinical studies. A phase II study of afatinib in EGFR-mutation positive lung...
Afatinib as First-line Treatment for Metastatic NSCLC with EGFR Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On July 12, 2013, afatinib (Gilotrif) was approved for...
SIDEBAR: Never Too Young Campaign's Collaborative Effort
The Colon Cancer Alliance’s mission is to knock colon cancer out of the top three cancer killers. The group works to promote prevention, fund cutting-edge research and provide the highest quality patient support services. For more information, visit www.ccalliance.org Bowel Cancer UK is a charity...
New Campaign Addresses Rise in Young-onset Colon Cancer
The Colon Cancer Alliance has partnered with Bowel Cancer UK and the Colon Cancer Prevention Project to launch the international Never Too Young awareness campaign, addressing the rise in young-onset (younger than 50 years) colon cancer diagnoses and mortality rates. This global collaboration comes ...
ASCO Studies Support Limited Use of 'Routine' Imaging
The overuse of imaging in oncology workup and surveillance is a timely concern, as health-care dollars shrink and the risk for second malignancies becomes clearer. At this year’s ASCO Annual Meeting, several studies showed that although many routine imaging studies may be unnecessary, physicians...
Targeted Suppression of a Reactivated Developmental Pathway in Hepatocellular Cancer
This issue of The ASCO Post summarizes the results of an important study recently published in The New England Journal of Medicine by Yong and colleagues. As outlined, investigators from the National University of Singapore Yong Loo Lin School of Medicine have identified re-expression of SALL4 as a ...
Oncofetal Protein SALL4 Is a Marker of Aggressive Hepatocellular Carcinoma and a Potential Therapeutic Target
Hepatocellular carcinomas with characteristics of embryonic stem cell and progenitor cell gene expression are associated with particularly poor prognosis. SALL4 is an oncofetal protein that is expressed in the human fetal liver and normally silenced in the adult liver, but re-expressed in a...
Diane E. Meier, MD: From Early Lessons in Critical Thinking to 'Palliative Care Everywhere'
Although the world is full of suffering, it is full also of the overcoming of it. —Helen Keller, Optimism, 1903 Shortly past 8:00 AM on July 1977, Diane E. Meier, MD, FACP, began the first day of her medical internship. Within minutes she would experience another first: the death of a patient...
Evolving Issues in Low-dose CT Lung Cancer Screening
Over a decade has passed since the start of the National Lung Cancer Screening Trial and more than 2 years since the first report indicating that this randomized study had demonstrated a significant reduction in lung cancer mortality with low-dose computed tomography (CT) screening.1 That favorable ...
Low-dose CT Screening for Lung Cancer: Details of First Round of Screening in National Lung Screening Trial
The National Lung Screening Trial found that 3 years of annual screening with low-dose helical computed tomography (CT) reduced lung cancer mortality compared with chest radiography in older persons who were heavy smokers.1 The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial also...
Where Are We With ALK Inhibition in Lung Cancer?
The prospective phase III PROFILE 1007 study compared the ALK inhibitor crizotinib (Xalkori) to chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with ALK gene–rearranged tumors refractory to previous chemotherapy. The study showed a clear superiority for crizotinib in terms ...
Crizotinib Improves Progression-free Survival vs Pemetrexed or Docetaxel in Advanced ALK-positive NSCLC
In a phase III trial reported by Alice T. Shaw, MD, PhD, a thoracic oncologist at Massachusetts General Hospital, Boston, and colleagues in The New England Journal of Medicine, crizotinib (Xalkori) improved progression-free survival compared with standard chemotherapy in previously treated patients ...
PET/CT Superior to Bone Marrow Biopsy for Diagnosis, Prognosis in Lymphoma
A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma has been identified by researchers in a study published recently in The Journal of Nuclear Medicine.1 Imaging with 18F–fluorodeoxyglucose positron-emission tomography/computed tomography...
Ibrutinib Produces High Response Rate in Patients with Refractory Mantle Cell Lymphoma
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase, a mediator of the B cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University of Texas MD Anderson...
High Rate of Durable Remissions with Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia
Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase is an essential component of B cell–receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of CLL cells....
CDC Report Shows Stagnated HPV Vaccination Rate for Girls
For the first time since the human papillomavirus (HPV) vaccine became available for adolescent girls in 2006, the vaccination rate for teenagers has stalled, according to data published in the Centers for Disease Control and Prevention’s (CDC’s) Morbidity and Mortality Weekly Report. The data...
